Breaking News Bar

Business News and Information

The Daily Herald Market Index
Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
Local Stocks
Nemus Bioscience (OP: NMUS)
0.4250 USD  UNCHANGED
Last Price  /  Updated: 12:31 PM EDT, Apr 9, 2019  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open 0.4250
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.4250
Today's Range 0.4250 - 0.4250
52wk Range N/A - N/A
Shares Outstanding 132,601,579
Dividend Yield N/A
Performance
Top News
More News
Emerald Bioscience to Participate in 29th Annual International Cannabinoid Research Symposium (ICRS)
from NewMediaWire
Emerald Biosciences NB2222 Exhibits Superior Ocular Permeation into Multiple Compartments of the Eye Compared to Cannabidiol
from NewMediaWire
More News
Read More
Emerald Bioscience to Present at the 9th Annual LD Micro Invitational
from NewMediaWire
Emerald Bioscience Secures "All Fields" Licenses for Cannabinoid Derivatives Developed by University of Mississippi
from NewMediaWire
Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference
from NewMediaWire
Emerald Bioscience Announces Ophthalmology Scientific Advisory Board Members
from NewMediaWire
Emerald Bioscience to Present at the 2019 H.C. Wainwright Global Life Sciences Conference
from NewMediaWire
Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act
from NewMediaWire
Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments
from NewMediaWire
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
from NewMediaWire
Nemus Bioscience Reports Nanoemulsion of NB1111 Superior to First-Line Therapy, Latanoprost, in Lowering Intraocular Pressure in Validated Normotensive Animal Model Testing
from GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear
Search DailyHerald.com for articles
More ways to search Daily Herald
Obituaries
Search DailyHerald.com obituaries. » Daily Herald newspaper archive
Find archived newspaper articles back to 1901. »
Digital Subscriptions
Activate Subscriber Access Purchase a Digital Subscription
Home Delivery
Start a New Subscription Manage Account